All‐cause mortality · women with primary biliary cirrhosis.
It is very uncertain whether hormone replacement changes all‐cause mortality compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Fracture · women with primary biliary cirrhosis.
It is very uncertain whether hormone replacement changes fractures compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Adverse events · women with primary biliary cirrhosis.
It is very uncertain whether hormone replacement changes adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Liver morbidity · women with primary biliary cirrhosis.
It is very uncertain whether hormone replacement changes liver‐related morbidity compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Bilirubin (µmol/L) · women with primary biliary cirrhosis.
1 finding from 1 review
Severity of STP at 24 hours post‐operatively · women undergoing a diagnostic or operative laparoscopic gynaecological procedure
1 finding from 1 review
Adverse events · women undergoing a diagnostic or operative laparoscopic gynaecological procedure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Analgesia usage · women undergoing a diagnostic or operative laparoscopic gynaecological procedure
1 finding from 1 review
Incidence of STP at 24 hours post‐operatively · women undergoing a diagnostic or operative laparoscopic gynaecological procedure
Intraperitoneal drain may leads to lower incidence of STP at 24 hours post‐operatively compared with no intraperitoneal drain (low certainty).
1 finding from 1 review
Incidence of upper body disorders (neck, shoulder, and upper extremity) Questionnaire followed by medical examination · office workers
Alternative mouse alone showed no clear difference in incidence of upper body disorder (neck, shoulder and upper… compared with conventional mouse alone (moderate certainty).
1 finding from 1 review
Incidence of neck/shoulder disorder Questionnaire followed by medical examination · office workers
Alternative mouse alone showed no clear difference in incidence of neck or shoulderdisorder Questionnaire followed by… compared with conventional mouse alone (low certainty).
1 finding from 1 review
Incidence of right upper extremity disorder Questionnaire followed by medical examination · office workers
Alternative mouse alone showed no clear difference in incidence of right upper extremity disorder Questionnaire followed… compared with conventional mouse alone (moderate certainty).
1 finding from 1 review
Neck/shoulder discomfort score Questionnaire · office workers
1 finding from 1 review
Right upper extremity discomfort score Questionnaire · office workers
1 finding from 1 review
Work related function · office workers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Intervention (no. of studies/participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Mitoxantrone (Direct evidence; 1 RCT; 51 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The intervention may leads to lower mitoxantrone (Direct evidence; 1 RCT; 51 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Intervention (no. of studies/participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Interferon beta‐1a (Avonex, Rebif) (Direct evidence; 3 RCTs; 1629 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention probably leads to lower interferon beta‐1a (Avonex, Rebif) (Direct evidence; 3 RCTs; 1629… (moderate certainty).
1 finding from 1 review
RR 0.84 [0.78, 0.91]
1 study · 3 participants
Moderate
Intervention not reported
Mitoxantrone (Direct evidence; 1 RCT; 51 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention may leads to lower mitoxantrone (Direct evidence; 1 RCT; 51 participants) (low certainty).
1 finding from 1 review